Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER vs MANNITOL 15% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mannitol is an osmotic diuretic that increases plasma osmolality, drawing water from intracellular spaces into the extracellular fluid and bloodstream, thereby reducing cerebral edema and promoting diuresis. Dextrose provides a source of calories and may help prevent hypoglycemia.
Mannitol is an osmotic diuretic that increases plasma osmolality, thereby drawing water from extravascular spaces into the plasma and reducing intracranial pressure. It also increases renal tubular osmotic pressure, inhibiting water reabsorption and promoting diuresis.
Reduction of intracranial pressure,Reduction of intraocular pressure,Promotion of diuresis in oliguric acute renal failure (prophylaxis or treatment),Osmotic diuresis for drug overdose (e.g., salicylates, barbiturates),Irrigation solution during transurethral prostatic resection
Reduction of elevated intracranial pressure (FDA-approved),Promotion of diuresis in acute renal failure (FDA-approved),Reduction of intraocular pressure (FDA-approved),Irrigant in transurethral prostatic resection (FDA-approved),Enhancement of urinary excretion of toxic substances (off-label)
Adult: 50-100 g (500-1000 m L of 10% solution) intravenously over 1-2 hours, repeated as needed every 6-12 hours. Individualize based on urine output and serum osmolality.
Intravenous: 50-100 g (1-2 g/kg) as a 15-25% solution over 30-60 minutes. For cerebral edema: 0.25-1 g/kg IV every 4-6 hours. For oliguric acute kidney injury: test dose of 0.2 g/kg IV over 3-5 minutes; if urine output >50 m L/hr, administer 50-100 g as 15-20% solution over 2-6 hours.
Terminal elimination half-life of mannitol is approximately 1.5-2 hours in patients with normal renal function. Clinically, duration of osmotic diuresis parallels half-life; in renal impairment, half-life may extend to 24-36 hours, increasing risk of fluid overload and electrolyte disturbances.
Terminal elimination half-life approximately 0.5–1 hour in normal renal function; prolonged to 24–36 hours in anuria or severe renal impairment.
Mannitol is not significantly metabolized; it is excreted unchanged by the kidneys. Dextrose is metabolized via glycolysis to pyruvate and lactic acid, and enters the Krebs cycle for energy production.
Mannitol is not metabolized; it is excreted unchanged by the kidneys via glomerular filtration, with a small amount reabsorbed in the proximal tubule.
Primarily renal excretion: Mannitol is filtered by glomeruli and not reabsorbed, excreted unchanged in urine (approximately 80-90% within 24 hours). Biliary/fecal elimination is negligible (<5%). Dextrose is metabolized to CO2 and water; any excess is excreted renally as glucose if threshold exceeded.
Renal: >90% excreted unchanged in urine within 24 hours; minimal biliary/fecal elimination (<2%).
Mannitol is not significantly bound to plasma proteins (<1%). Dextrose is not protein bound.
Negligible protein binding (<0.5%); no specific binding proteins identified.
Approximately 0.5-0.6 L/kg. Mannitol distributes primarily in extracellular fluid (ECF); it does not enter cells significantly. Clinically, this low Vd indicates confinement to ECF, important for osmotic effects.
Approximately 0.5–0.7 L/kg (confined to extracellular fluid space; does not cross cell membranes significantly).
Intravenous: 100% bioavailability. Oral bioavailability is negligible (<10%) as mannitol is poorly absorbed and acts as an osmotic laxative; Dextrose is well absorbed orally (100%) but not relevant for this IV formulation.
Intravenous: 100% (only route used clinically); no oral bioavailability due to poor absorption and osmotic diarrhea.
Contraindicated in anuria or severe renal impairment (GFR < 20 m L/min). For GFR 20-50 m L/min, use with caution and monitor serum osmolality; reduce dose or extend interval. No specific dose reduction formula established.
Contraindicated in anuria. GFR <15 m L/min: avoid use. GFR 15-30 m L/min: use with caution, monitor serum osmolarity and electrolytes. No specific dose adjustment for mild-moderate renal impairment; clinical judgment required.
No specific adjustments required for hepatic impairment. Monitor fluid and electrolyte balance due to potential volume expansion.
No specific dose adjustment for hepatic impairment; monitor for fluid and electrolyte disturbances.
0.25-1 g/kg (2.5-10 m L/kg of 10% solution) intravenously over 30-60 minutes, repeated as needed. Max dose 2 g/kg/day. Adjust based on response and serum osmolality.
Intravenous: 1-2 g/kg as a 15-20% solution over 30-60 minutes. For acute renal failure: test dose of 0.2 g/kg IV over 30 minutes; if urine output >1 m L/kg/hr, continue with 0.5-1 g/kg every 4-6 hours. For cerebral edema: 0.25-1 g/kg IV every 4-6 hours. Maximum infusion rate: 60 g/hour.
Use lower initial doses and monitor renal function and electrolytes closely due to age-related decline in renal function and higher risk of volume overload. Start at 25-50 g (250-500 m L of 10% solution) and titrate.
Start at lower end of dosing range; monitor renal function, fluid balance, and electrolytes closely due to age-related decreased renal function and higher risk of volume overload.
None.
None.
Monitor serum electrolytes, osmolality, and renal function during therapy,May cause fluid and electrolyte imbalances, including hyponatremia or hypernatremia,Administer cautiously in patients with renal impairment, heart failure, or pulmonary edema,Use with caution in conditions where increased intravascular volume may be harmful,Do not administer if solution contains particulate matter or is discolored
Use with caution in patients with heart failure, pulmonary congestion, or renal impairment due to risk of fluid overload and electrolyte disturbances.,Monitor serum electrolytes, osmolality, and renal function during therapy.,Avoid in patients with anuria due to severe renal disease.,Rapid infusion may cause circulatory overload resulting in hyponatremia and hyperosmolality.
Anuria due to severe renal disease,Severe dehydration,Intracranial hemorrhage (unless during craniotomy),Active intracranial bleeding except during craniotomy,Hypersensitivity to mannitol or dextrose,Congestive heart failure,Pulmonary edema
Anuria due to severe renal disease,Severe pulmonary congestion or edema,Active intracranial bleeding (except during craniotomy),Dehydration,Hypersensitivity to mannitol
No clinically relevant food interactions.
No specific food interactions. Maintain adequate hydration unless contraindicated. Avoid excessive salt intake as it may counteract diuretic effect.
No evidence of teratogenicity in animal studies; limited human data. Mannitol crosses the placenta; risk of fetal electrolyte disturbances and dehydration with maternal overdose. First trimester: theoretical risk only, no reported malformations. Second/third trimesters: monitor for maternal hyperosmolality and fluid shifts which may affect fetal hydration status.
Mannitol is a pregnancy category C drug. There are no adequate and well-controlled studies in pregnant women. Animal studies have not been conducted. Mannitol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. In the first trimester, risks are unknown; in second and third trimesters, maternal administration may cause fetal electrolyte disturbances due to osmotic diuresis.
Not known if mannitol or dextrose are excreted in breast milk. Consider risk of osmotic diarrhea in neonate if present in milk. M/P ratio not established.
It is not known whether mannitol is excreted in human milk. The M/P ratio is not established. Caution should be exercised when mannitol is administered to a nursing woman. The drug should be used only if clearly needed, considering the potential for adverse effects in nursing infants such as osmotic diuresis and electrolyte imbalance.
No specific dose adjustment recommended; monitor maternal fluid status closely as pregnancy increases risk of pulmonary edema; adjust rate based on urine output and osmolality.
Pregnancy may alter pharmacokinetics of mannitol due to increased plasma volume and renal blood flow, potentially increasing clearance. However, specific dose adjustments are not recommended. The usual adult dose (50-200 g per 24 hours) may be used with careful monitoring of maternal hydration status, urine output, and serum osmolality to avoid volume depletion or overload. No standard dose reduction is indicated.
Monitor serum sodium and osmolality closely; risk of hypernatremia and acute kidney injury. Use an in-line filter to prevent crystallization. Administer by slow IV infusion to avoid fluid overload. Contraindicated in anuria and severe pulmonary edema.
Mannitol 15% is an osmotic diuretic used primarily for reduction of intracranial pressure (ICP) and cerebral edema. In emergency settings, administer via IV bolus (0.25-1 g/kg) over 30-60 minutes; onset of ICP reduction occurs within 15-30 minutes. Monitor serum osmolality and avoid if >320 m Osm/L. Use with caution in acute tubular necrosis. Can cause transient volume expansion followed by diuresis; watch for pulmonary edema in heart failure patients. Crystallization may occur at low temperatures; warm and inspect before use.
Report any signs of fluid overload like shortness of breath or swelling.,This medicine may cause increased urination and thirst.,Do not take this medication by mouth; it is for intravenous use only.,Inform your healthcare provider if you have kidney problems or heart failure.
This medication is given intravenously to reduce swelling in the brain.,You may experience increased urination, headache, or dry mouth.,Report any chest pain, difficulty breathing, or unusual swelling.,Do not stop or change the infusion rate without medical advice.,Tell your doctor if you have kidney disease, heart failure, or electrolyte imbalances.
"Concomitant use of clonidine and mannitol may potentiate the hypotensive effect of clonidine, leading to an increased risk of severe hypotension, syncope, and orthostatic hypotension. Mannitol, an osmotic diuretic, can cause volume depletion and electrolyte disturbances, which may exacerbate clonidine's sympatholytic effects on blood pressure regulation. This interaction is particularly concerning in patients with pre-existing cardiovascular conditions or those receiving other antihypertensive agents."
"Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances."
"Coadministration of candesartan cilexetil, an angiotensin II receptor blocker (ARB), with mannitol, an osmotic diuretic, can result in an additive hypotensive effect due to overlapping mechanisms that reduce blood pressure. Mannitol increases renal water excretion, decreasing plasma volume and preload, while candesartan inhibits angiotensin II-mediated vasoconstriction and aldosterone secretion, leading to vasodilation and reduced afterload. This combined effect may predispose patients to symptomatic hypotension, especially in those with volume depletion or renal impairment."
"Concomitant use of clonidine and mannitol may potentiate the hypotensive effect of clonidine, leading to an increased risk of severe hypotension, syncope, and orthostatic hypotension. Mannitol, an osmotic diuretic, can cause volume depletion and electrolyte disturbances, which may exacerbate clonidine's sympatholytic effects on blood pressure regulation. This interaction is particularly concerning in patients with pre-existing cardiovascular conditions or those receiving other antihypertensive agents."
"Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances."
"Coadministration of candesartan cilexetil, an angiotensin II receptor blocker (ARB), with mannitol, an osmotic diuretic, can result in an additive hypotensive effect due to overlapping mechanisms that reduce blood pressure. Mannitol increases renal water excretion, decreasing plasma volume and preload, while candesartan inhibits angiotensin II-mediated vasoconstriction and aldosterone secretion, leading to vasodilation and reduced afterload. This combined effect may predispose patients to symptomatic hypotension, especially in those with volume depletion or renal impairment."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER vs MANNITOL 15% IN PLASTIC CONTAINER, answered by our medical review team.
MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER is a Osmotic Diuretic that works by Mannitol is an osmotic diuretic that increases plasma osmolality, drawing water from intracellular spaces into the extracellular fluid and bloodstream, thereby reducing cerebral edema and promoting diuresis. Dextrose provides a source of calories and may help prevent hypoglycemia.. MANNITOL 15% IN PLASTIC CONTAINER is a Osmotic Diuretic that works by Mannitol is an osmotic diuretic that increases plasma osmolality, thereby drawing water from extravascular spaces into the plasma and reducing intracranial pressure. It also increases renal tubular osmotic pressure, inhibiting water reabsorption and promoting diuresis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER and MANNITOL 15% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Osmotic Diuretic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER is: Adult: 50-100 g (500-1000 m L of 10% solution) intravenously over 1-2 hours, repeated as needed every 6-12 hours. Individualize based on urine output and serum osmolality.. The standard adult dose of MANNITOL 15% IN PLASTIC CONTAINER is: Intravenous: 50-100 g (1-2 g/kg) as a 15-25% solution over 30-60 minutes. For cerebral edema: 0.25-1 g/kg IV every 4-6 hours. For oliguric acute kidney injury: test dose of 0.2 g/kg IV over 3-5 minutes; if urine output >50 m L/hr, administer 50-100 g as 15-20% solution over 2-6 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER and MANNITOL 15% IN PLASTIC CONTAINER. Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER is classified as Category A/B. No evidence of teratogenicity in animal studies; limited human data. Mannitol crosses the placenta; risk of fetal electrolyte disturbances and dehydration with maternal overdose. F. MANNITOL 15% IN PLASTIC CONTAINER is classified as Category A/B. Mannitol is a pregnancy category C drug. There are no adequate and well-controlled studies in pregnant women. Animal studies have not been conducted. Mannitol should be used during. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.